Nivolumab Plus Low-Dose Ipilimumab Demonstrates Clinical Benefit in First-Line Treatment for MSI-H/dMMR mCRC
Findings from the CheckMate 142 study in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer